Customer No. 35743 Attorney Docket No. 57637/1185

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Arbogast et al.

Confirmation No.: 6754

Serial No.:

10/661,032

Filing Date:

September 11, 2003

Examiner:

To be assigned

Group Art Unit:

1616

For:

MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on:

Date:

..

Carrie L. Caggi

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants respectfully submit this *Information Disclosure Statement* pursuant to 37 C.F.R. §§ 1.97 and 1.98 in order to comply with the duty of disclosure under 37 C.F.R. § 1.56. These references are listed on the attached modified PTO Form No. 1449. A copy of each of the listed references are enclosed for the convenience of the Examiner.

This *Information Disclosure Statement* is being mailed before the mailing date of the first Office Action on the merits, and thus, pursuant to 37 C.F.R. § 1.97(b), Applicants respectfully request that the information be expressly considered during the prosecution of this application and that the references be made of record therein and appear among the "References

Cited" on any patent to issue therefrom. Applicants further request that a copy of the PTO Form No. 1449, appropriately initialed by the Examiner, be returned to Applicants' attorneys.

No fees are believed to be due in connection with the filing of this *Information*Disclosure Statement. However, the Director is authorized to charge any fees due, or credit any overpayments, to Deposit Account No. 50-0540.

Dated: July 8, 2005

Respectfully submitted,

Rachel J. Fin Reg. No. 51,098 Donald Rhoads, Reg. No. 34,705

Rachel J. Lin, Reg. No. 51,098

Attorneys for Applicants

KRAMER LEVIN NAFTALIS & FRANKEL LLP

1177 Avenue of the Americas

New York, New York 10036

(212) 715-9100

(212) 715-8000

Based on Form PTO-1449 (3/90)				ATTY. DOCKET NO. 57637/1185		SERIAL NO. 10/661,032		
		NCES CITED BY APP ral sheets if necessary)	PLICANT					
OIPA	350 50.0.	ui sheets ii neeessary)	APPLICANTS					
	<i>હ</i>			Arbogast et al.				
	-			FILING DATE GROUP AR			RT IINIT	
_ JUL 1 3 200	15 ^(r)			September 11, 2003		1614	iki Oivii	
JUL 1 3 200	- luj - S?/		HC DAT	ENT DOCUMENTS		1014		
(E)	16.		U.S. PA1	ENT DOCUMENTS	1	<u> </u>	FILING	
EXAMINER EXAMINER		DOCUMENT				SUB-	DATE IF	
INITIAL		NUMBER	DATE	NAME	CLASS	CLASS	APPROPRIATE	
INITIAL	AA	2,913,451	11-17-59	De La Mater et al.	CLASS	CLASS	APPROPRIATE	
	AB	5,861,301	6-19-99	Terman et al.				
	AC	5,766,860	6-16-98	Terman et al.				
	AD	6,204,011	3-20-01	Kendall et al.	·			
	AE	6,359,115	3-20-01	Kendall et al.				
	AF	6,146,657	11-14-00	Unger et al.	 	+		
	AG	6,071,495	6-6-00	Unger et al.		-		
	AH	5,773,024	6-30-98	Unger et al.		_		
	AI	5,769,080	6-23-98	Unger et al.		_		
	AJ	6,261,535	7-17-01	Thorpe et el.	<u> </u>			
	AK	6,051,230	4-18-00	Thorpe et al.				
	AL	5,885,866	1-5-99	Thorpe et al.	· · · · · · · · · · · · · · · · · · ·			
	AM	US2003/0023046	1-30-03	Ferrara et al.				
	AN	US2002/0098187	7-25-02	Ferrara et al.	1			
	AO	5,935,820	8-10-99	Hu et al.				
	AP	US2003/0091567	5-13-03	Alitalo et al.		- -		
	AQ	6,521,211	2-3-99	Unger et al.				
	AR	6,221,839	4-24-01	Alitalo et al.				
	AS	6,245,530	6-12-01	Alitalo et al.				
	AT	6,403,088	6-11-02	Alitalo et al.			· · · · · · · · · · · · · · · · · · ·	
	AU	6,645,933	11-11-03	Alitalo et al.				
	AV	6,576,608	6-10-03	Lee et al.	· · · · · · · · · · · · · · · · · · ·	-		
	AW	6,451,764	9-17-02	Lee et al.				
	AX	6,361,946	3-26-02	Alitalo et al.				
4.4	AY	6,331,289	12-18-01	Klaveness et al.				
	AZ	6,261,537	7-17-01	Klaveness et al.	1			
	AAA	6,264,917	7-24-01	Klaveness et al.	1			
	AAB	US2002/0001566	1-3-02	Rajopadhye et al.				
	AAC	US2002/0015680	2-7-02	Harris				
	AAD	6,322,770	11-27-01	Rajopadhye et al.				
	AAE	US2003/0180305	9-25-03	Rajopadhye et al.				
	AAF	US2002/0065218	5-30-02	Achen et al.				
	AAG	US2002/0102260	8-1-02	Achen et al.				
	AAH	US2001/0038842	11-8-01	Achen et al.				
	AAI	US2001/0031485	10-18-01	Backer et al.				
	AAJ	6,689,352	2-10-04	Achen et al.				
	AAK	US2003/0082103	5-1-03	Wartchow et al.	ļ			
· · · · · · · · · · · · · · · · · · ·	AAL	US2002/0068697	6-6-02	Tournaire				
	AAM	US2003/0176674	9-18-03	Rosen et al.				
	AAN	US2002/0086013	7-4-02	King				
	AAO	US2002/0091082	7-11-02	Aiello	ļ			
	AAP	US2004/0033949	2-19-04	Bunting	<u></u>			
	AAQ		<u> </u>					

DOCUMENT DATE COUNTRY CLASS SUB- TRANSLATIO				FENT DOCUMENTS		T		
BA		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLA	AOIT.
BC	BA		06/03/03	WO				
BD	BB	WO 02/060950	8-8-02	WO				1
BE	BC	WO 96/40285	12-19-96	WO		i –		
BF	BD	WO 03/080653	02/10/03	WO				
BH	BE	WO 01/70681	27/09/01	WO				
BI	BF		24/01/02	WO		<u> </u>		
BJ WO 97/09427 3-13-97 WO BK WO 97/17422 5-15-97 WO BL WO 98/18501 5-7-98 WO WO SI	BH	WO 94/10202	5-11-94	WO				
BK	BI	EP 1238986	9-11-02	EP				
BL	BJ	WO 97/09427	3-13-97	WO				
BM	BK	WO 97/17422	5-15-97	WO				
BN WO 98/47541 10-29-98 WO BO WO 99/29861 6-17-99 WO BP WO 99/40947 8-19-99 WO WO 99/58162 11-18-99 WO BR WO 09/27414 5-18-00 WO BR WO 00/27414 5-18-00 WO BS WO 00/45856 8-10-00 WO BT WO 01/47284 6-14-01 WO WO BT WO 01/54723 8-2-01 WO WO BV WO 01/62942 8-30-01 WO BW WO 01/64235 9-7-01 WO BW WO 01/64235 9-7-01 WO BW WO 01/69425 9-27-01 WO BZ WO 01/70945 9-27-01 WO BZ WO 01/70945 9-27-01 WO BZ WO 01/70968 9-27-01 WO BBA WO 01/83693 11-18-01 WO BBA WO 01/83693 11-18-01 WO BBB WO 01/87503 12-27-01 WO BBB WO 01/97850 12-27-01 WO BBB WO 01/97850 12-27-01 WO BBB EP 1166799 1-2-02 EP BBB EP 1166799 1-2-02 EP BBB WO 02/07747 1-31-02 WO BBB WO 02/073299 7-25-02 WO BBB WO 03/028643 4-10-03 WO BBB WO 03/028643 4-10-03 WO BBB WO 03/028643 4-10-03 WO BBB WO 03/028895 4-11-02 WO BBB WO 02/03895 4-11-02 WO BBB WO 02/03895 4-11-02 WO BBB WO 02/04448 9-3-92 WO BBB WO 02/047448 9-3-92 WO BBB WO 02/04617 11-20-03 WO BBB WO 02/04448 9-3-92 WO BBB WO 02/04617 11-20-03 WO BBB WO 02/044018 11-20-03 WO BBB WO 02/04448 9-3-92 WO WO WO WO WO WO WO W	BL	WO 98/18501	5-7-98	WO				
BO	BM		5-7-98	WO				
BP WO 99/40947 8-19-99 WO BR WO 09/58162 11-18-99 WO BR WO 00/27414 5-18-00 WO BR WO 00/27414 5-18-00 WO BS WO 00/45856 8-10-00 WO BS WO 01/45284 6-14-01 WO WO BU WO 01/54723 8-2-01 WO WO BU WO 01/54723 8-2-01 WO WO WO BW WO 01/64235 9-7-01 WO BW WO 01/64235 9-7-01 WO BX EP 1259248 12-15-04 EP BY WO 01/70945 9-27-01 WO BZ WO 01/70945 9-27-01 WO BBA WO 01/83693 11-18-01 WO WO WO WO WO WO WO W	BN							
NQ	ВО							
BR	BP		8-19-99	WO				
BS	NQ	WO 99/58162						
BT								
BU WO 01/54723 8-2-01 WO BW WO 01/62942 8-30-01 WO WO WO SW WO 01/62942 8-30-01 WO WO WO SW WO 01/62345 9-7-01 WO WO SW WO 01/70945 9-27-01 WO WO SW WO 01/70945 9-27-01 WO WO SW WO 01/70945 9-27-01 WO WO SW WO 01/80593 11-18-01 WO SW WO 01/82870 11-18-01 WO SW WO 01/97850 12-27-01 WO SW WO 01/97850 12-202 EP SW SW WO 01/97471 1-31-02 WO SW WO 01/97481 10-24-02 WO SW WO 01/97481 10-24-02 WO SW WO 01/97481 11-20-03 WO SW WO 01/97481 11-20-03 WO SW WO 01/97481 11-20-03 WO SW SW WO 01/97481 11-20-03 WO SW SW WO 01/97481 11-20-03 WO SW WO 01/97498382 2-14-03 JP WO 01/974983								
BV WO 01/62942 8-30-01 WO BW WO 01/64235 9-7-01 WO BW WO 01/64235 9-7-01 WO BX EP 1259248 12-15-04 EP BY WO 01/70945 9-27-01 WO BZ WO 01/70268 9-27-01 WO BZ WO 01/70268 9-27-01 WO BBA WO 01/83693 11-18-01 WO BBB WO 01/82870 11-18-01 WO BBB WO 01/97850 12-27-01 WO BBD EP 1166798 12-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBB WO 02/057299 7-25-02 WO BBH WO 02/057299 7-25-02 WO BBH WO 02/053349 10-24-02 WO BBH WO 02/038349 10-24-02 WO BBH WO 03/028643 4-10-03 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/04617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBL WO 92/14748 PROPERTOR OF PROPERTOR O								<u> </u>
BW WO 01/64235 9-7-01 WO BX EP 1259248 12-15-04 EP BY WO 01/70945 9-27-01 WO BZ WO 01/70268 9-27-01 WO BZ WO 01/70268 9-27-01 WO BBA WO 01/83693 11-18-01 WO BBBA WO 01/83693 11-18-01 WO BBB WO 01/82870 11-18-01 WO BBC WO 01/97850 12-27-01 WO BBD EP 1166798 1-2-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBG WO 02/07747 1-31-02 WO BBH WO 02/0873849 10-24-02 WO BBH WO 02/083849 10-24-02 WO BBH WO 03/028643 4-10-03 WO BBB WO 03/028643 4-10-03 WO BBB WO 03/028895 4-11-02 WO BBB WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBL WO 92/14								<u> </u>
BX								<u> </u>
BY WO 01/70945 9-27-01 WO								ļ
BZ WO 01/70268 9-27-01 WO BBA WO 01/83693 11-18-01 WO BBB WO 01/82870 11-18-01 WO BBC WO 01/97850 12-27-01 WO BBD EP 1166798 1-2-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBH WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/028643 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBK WO 09/14748 9-3-92 WO BBK WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								ļ
BBA WO 01/83693 11-18-01 WO BBB WO 01/82870 11-18-01 WO BBC WO 01/97850 12-27-01 WO BBD EP 1166798 1-2-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBH WO 02/07747 1-31-02 WO BBH WO 02/083849 10-24-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBH WO 92/14748 9-3-92 WO BCH WO 92/14748 9-3-92 WO BCH WO 92/14748 POS-3-92 WO BCH WO 92/147493 POS-3-92 WO BCH WO 92/147493 POS-3-92 WO BCH WO 92/147493 POS-3-93 POS-3		,,,						
BBB WO 01/82870 11-18-01 WO BBC WO 01/97850 12-27-01 WO BBD EP 1166798 1-2-02 EP BBF EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBH JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"						<u></u>		-
BBC WO 01/97850 12-27-01 WO BBD EP 1166798 1-2-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBI WO 03/028695 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								
BBD EP 1166798 1-2-02 EP BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993, 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								
BBE EP 1166799 1-2-02 EP BBF WO 02/07747 1-31-02 WO BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBJ WO 03/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"						ļ		 —
BBF WO 02/07747 1-31-02 WO BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally synthetic immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								-
BBG WO 02/057299 7-25-02 WO BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								
BBH WO 02/083849 10-24-02 WO BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K.; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998; CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"						ļ		
BBI WO 03/028643 4-10-03 WO BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"	1 0				_	ļ		
BBJ WO 02/028895 4-11-02 WO BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally synthetic immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998; CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"			· · · · · · · · · · · · · · · · · · ·			ļ		 -
BBK WO 03/094617 11-20-03 WO BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998; CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								
BBL WO 92/14748 9-3-92 WO BBM JP 3398382 2-14-03 JP OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								_
OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"								-
OTHER PUBLICATIONS (Including Author, Title, Date, Pertinent Pages, Etc.) CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally syntheti immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"						<u> </u>		
CA Gestwicki, J.E.; Cairo, C.W.; Strong, L.E.; Oetjen, K.A. and Kiessling, L. L. Influencing Receptor-Ligan Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally synthetic immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998, 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"	DDIVI				Pertinent Page	s, Etc.)		J
Binding Mechanisms with Multivalent Ligand Architecture. J. Am. Chem. Soc. 2002, 124, 14922-14933 CB Jackson, D. C.; Fitzmaurice, C. J.; Brown, L. E.; Zeng, W. Preparation and properties of totally synthetic immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"			1		-			
immunogens. Vaccine 1999, 18, 355-361. CC Ben-Yedidia, T.; Arnon, R. Design of peptide and polypeptide vaccines. Current Opinion in Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1993 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"	CA	Binding Mechanisms	with Multivalen	t Ligand Architecture.	J. Am. Chem.	Soc. 2002, 1	24, 14922-14	1933.
Biotechnology 1997, 8, 442-448. Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"		immunogens. Vacci	ne 1999, 18, 35	5-361.	-			theti
Mammen, M.; Choi, S-K; and Whitesides, G.M. Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Edn. Engl. 1998 CD 37, 2754-2794. CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"	CC	Biotechnology 1997	, 8, 442-448.					
CE Pillai et al., "A novel and flexible method for preparation of peptide homo- and heterodimers functionalized with affinity probes, reported molecules and chelating ligands"	CD	Implications for design						1998
		Pillai et al., "A novel					limers	
	CE						notionalizad	with

•	CG	O'Brien-Simpson, N. M.; Ede, N. J.; Brown, L. E.; Swan, J.; Jackson, D. C. Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines. Journal of the American
	СН	Chemical Society 1997, 119, 1183-1188. A general review: Sadler, Kristen; Tam, James P. Peptide dendrimers: applications and synthesis. Reviews in Molecular Biotechnology 2002, 90(3-4), 195-229.
	CI	Futaki, S. Creation of ion channel function using synthetic peptides. (1998) Yuki Gosei Kagaku Kyokaishi 56, 125-133.
	CJ	Loffet, A. Q. Peptides as drugs: is there a market? In: <i>Peptides: The Wave of the Future, Proceedings of the Second International and the Seventeenth American Peptide Symposium, San Diego, CA, United States, June 9-14, 2001; Lebl, M., and Houghten, R. A. Eds.; American Peptide Society: San Diego, Calif. 2001; pp. 214-216.</i>
	CK	De Villiers, M. M., Liebenberg, W., Malan, S. F., and Gerber, J. J. (2000) Solubilization of poorly water soluble non-steroidal anti-inflammatory drugs at low pH with N-methylglucamine. S. Afr. Pharmazie, 55, 544-546.
	CL	Bajusz, S. (2003) Peptide related drug research. J. Pept. Sci. 9, 321-332.
	СМ	Souriau, C., and Hudson, P. J. (2001) Recombinant antibodies for cancer diagnosis and therapy. Expert Opin. Biol. Ther. 1, 845-855.
	CN	Mammen, M., Choi, S-K, and Whitesides, G. M. (1998) Polyvalent interactions in biological systems: Implications for design and use of multivalent ligands and inhibitors. <i>Angew. Chem., Int. Edn.</i> 37, 2754-2794.
	СО	Gestwicki, J. E., Cairo, C. W., Strong, L. E., Oetjen, K. A., and Kiessling, L. L. (2002) Influencing Receptor-Ligand Binding Mechanisms with Multivalent Ligand Architecture. <i>J. Am. Chem. Soc. 124</i> , 14922-14933.
	СР	Tam, J. P., Lu, Y-A., and Yang, J-L. (2002) Antimicrobial Dendrimeric Peptides. Eur. J. Biochem. 269, 923-932.
	CQ	Liu, S., Edwards, D. S., Ziegler, M. C., Harris, A. R., Hemingway, S. J., and Barret, J. A. (2001) ^{99m} Tc-Labeling of Hydrazinonicotiniamide-Conjugated Vitronection Receptor Antagonist Useful for Imaging Tumors. <i>Bioconjugate Chem.</i> 12, 624-629.
	CR	Hillairet de Boisferon, M., Raguin, O., Dussaillant, M., Rostène, W., Barbet, J., and Gruaz-Guyon, A. (2000) Enhanced Targeting Specificity to Tumor Cells by Simultaneous Recognition of Two Antigens. <i>Bioconjugate Chem. 11</i> , 452-460.
	CS	Schaffer, L., Brissette, R. E., Spetzler, J. C., Pillutla, R. C., Østergaard, S., Lennick, M., Brandt, J., Fletcher, P. W., Danielsen, G. M., Hsaio, K-C., Andersen, A. S., Dedova, O., Ribel, U., Hoeg-Jensen, T., Hansen, P.H., Blume, A.J., Markussen, J., and Goldstein, N.I. (2003) Assembly of High Affinity Insulin Receptor Agonists and Antagonists from Peptide Building Blocks. <i>Proc. Natl. Acad. Sci. U.S.A.</i> 100, 4435-4439.
	CT	Jackson, D. C., Fitzmaurice, C. J., Brown, L. E., and Zeng, W. (1999) Preparation and properties of totally synthetic immunogens. <i>Vaccine 18</i> , 355-361.
	CU	Ben-Yedidia, T., and Arnon, R. (1997) Design of peptide and polypeptide vaccines. Curr. Opin. Biotechnol. 8, 442-448.
	CV	O'Brien-Simpson, N. M., Ede, N. J., Brown, L. E., Swan, J., and Jackson, D. C. (1997) Polymerization of Unprotected Synthetic Peptides: A View toward Synthetic Peptide Vaccines. J. Am. Chem. Soc. 119, 1183-1188.
	CW	Chen, H., Holl, M-B., Orr, B. G., Majoros, I., and Clarkson, B. H. (2003) Interaction of dendrimers (artificial proteins) with biological hydroxyapatite crystals. <i>J. Dent. Res.</i> 82, 443-448.
	CX	Sal-Man, N., Oren, Z., and Shai, Y. (2002) Preassembly of membrane-active peptides is an important factor

CY	Lucke, A. J., Tyndall, J. D. A., Singh, Y., and Fairlie, D. P. (2003) Designing supramolecular structures from models of cyclic peptide scaffolds with heterocyclic constraints. <i>J. Mol. Graphics Modell.</i> 21, 341-355.
CZ	Mutter, M. and Tuchscherer, G. (2000) Evolution versus design: template-directed self-assembly of peptides to artificial proteins (TASP). Chimia 54, 552-557.
CCA	Todorovska, A., Roovers, R.C., Dolezal, O., Kortt, A. A., Hoogenboom, H. R., and Hudson, P. J. (2001) Design and Application of Diabodies, Triabodies and Tetrabodies for Cancer Targeting. <i>J. Immunol. Methods</i> 248, 47-66.
CCB	Veprek, P. and Jezek, J. (1999) Peptide and glycopeptide dendrimers. Part I. J. Pept. Sci. 5, 5-23.
CCC	Veprek, P. and Jezek, J. (1999) Peptide and glycopeptide dendrimers. Part II. J. Pept. Sci. 5, 203-220.

EXAMINER		DATE CONSIDERED
	CAA	the Third International and Twenty-Eight European Peptide Symposium, Prague, Czech Republic, September 5-10, 2004.
	ССМ	Pillai et al., "A Novel and Flexible Method for Preparation of Peptide Homo and Heterodimers Functionalized with Affinity Probes, Peporter Molecules and Chelating Ligands" Poster Presentation at
	CCL	Melkko et al. "Encoded self-assembling chemical libraries" <i>Nature Biotechnology</i> , Vol. 22, No. 5, May 2004, pp. 568-574.
	CCK	Sole, N. A., and Barany, G. (1992) Optimization of solid-phase synthesis of [Ala ⁸]-Dynorphin A. J. Org. Chem. 57, 5399-5403.
	CC1	Dawson, P.E. and Kent, S.B.H. (2000) Synthesis of Native Proteins by Chemical Ligation. Ann. Rev. Biochem. 69, 923-960.
	CCI	Offer, J., Boddy, C. N. C., and Dawson, P. E. (2002) Extending Synthetic Access to Proteins with a Removable Acyl Transfer Auxiliary. <i>J. Am. Chem. Soc.</i> 124, 4642-4646.
	ССН	Tam, J.P., Yu, Q., and Yang, J-L. (2001) Tandem Ligation of Unprotected Peptides through Thiaprolyl and Cysteinyl Bonds in Water. J. Am. Chem. Soc. 123, 2487-2494.
	CCG	Merkx, R., Rijkers, D. T. S., Kemmink, J., and Liskamp, R. M. J. (2003) Chemoselective coupling of peptide fragments using the Staudinger ligation. <i>Tetrahedron Lett.</i> 44, 4515-4518.
	CCF	Thumshirn, G., Hersel, U., Goodman, S. L., and Kessler, H. (2003) Multimeric cyclic RGD peptides as potential tools for tumor targeting: Solid-phase peptide synthesis and chemoselective oxime ligation. <i>Chem.—Eur. J. 9</i> , 2717-2725.
	CCE	Hunter, C. L., and Kochendoerfer, G. G. (2004) Native Chemical Ligation of Hydrophobic Peptides in Lipid Bilayer Systems <i>Bioconjugate Chem.</i> 15, 437-440.
	CCD	A general review: Sadler, K. and Tam, J. P. (2002) Peptide dendrimers: applications and synthesis. <i>Rev. Mol. Biotechnol. 90</i> , 195-229.

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.